As cytokines play a relevant role in the expansion and survival of lymphocytes, both high-dose and low-dose IL-2 have been used for adoptive cell therapy using autologous tumor-infiltrating lymphocytes for melanoma treatment: a systematic review and meta-analysis evidenced the ability of high dose-IL-2 to induce durable clinical benefit when combined with adoptive cell therapy [54]. This evidence concerns the gene IL2 and neoplasm.